ILK and ovarian carcinoma: Reyes-Gonzalez et al. showed that both ILK-siRNA and CP22 reduced cell growth, invasion ability and increased apoptosis in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines [35].